Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Randomized Double-blinded Controlled Phase 2 Study Evaluating the Efficacy of Valganciclovir as add-on Therapy in Glioblastoma Patients

NCT04116411 is registered in ClinicalTrials.gov with Cecilia Soderberg-Naucler as lead sponsor.

NCT NCT04116411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04116411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Randomized Double-blinded Controlled Phase 2 Study Evaluating the Efficacy of Valganciclovir as add-on Therapy in Glioblastoma Patients
Lead sponsor
Cecilia Soderberg-Naucler
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 4, 2019
Completion date
September 16, 2027
Enrollment
220 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme